Teladoc Health, Inc. (NYSE:TDOC) Shares Sold by Vanguard Group Inc.

Vanguard Group Inc. decreased its position in Teladoc Health, Inc. (NYSE:TDOC) by 9.6% in the 3rd quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 15,659,647 shares of the health services provider’s stock after selling 1,654,104 shares during the quarter. Vanguard Group Inc. owned about 9.46% of Teladoc Health worth $291,113,000 as of its most recent filing with the Securities and Exchange Commission.

Several other institutional investors have also recently added to or reduced their stakes in the company. Sunbelt Securities Inc. raised its stake in Teladoc Health by 3.7% in the 3rd quarter. Sunbelt Securities Inc. now owns 24,877 shares of the health services provider’s stock valued at $462,000 after purchasing an additional 899 shares during the last quarter. Deutsche Bank AG grew its holdings in Teladoc Health by 12.4% in the 3rd quarter. Deutsche Bank AG now owns 301,147 shares of the health services provider’s stock valued at $5,598,000 after buying an additional 33,287 shares during the period. Mercer Global Advisors Inc. ADV grew its holdings in Teladoc Health by 39.6% in the 3rd quarter. Mercer Global Advisors Inc. ADV now owns 21,790 shares of the health services provider’s stock valued at $405,000 after buying an additional 6,180 shares during the period. The Manufacturers Life Insurance Company purchased a new stake in Teladoc Health in the 3rd quarter valued at about $517,000. Finally, GSA Capital Partners LLP purchased a new stake in Teladoc Health in the 3rd quarter valued at about $1,149,000. Institutional investors and hedge funds own 76.82% of the company’s stock.

Insider Activity at Teladoc Health

In related news, CMO Stephany Verstraete sold 7,945 shares of the company’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $14.52, for a total transaction of $115,361.40. Following the sale, the chief marketing officer now directly owns 56,486 shares of the company’s stock, valued at approximately $820,176.72. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. In other news, EVP Andrew Turitz sold 6,190 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $89,878.80. Following the completion of the transaction, the executive vice president now owns 39,429 shares of the company’s stock, valued at $572,509.08. The transaction was disclosed in a document filed with the SEC, which is available at the SEC website. Also, CMO Stephany Verstraete sold 7,945 shares of the stock in a transaction on Monday, March 4th. The stock was sold at an average price of $14.52, for a total value of $115,361.40. Following the completion of the transaction, the chief marketing officer now directly owns 56,486 shares of the company’s stock, valued at approximately $820,176.72. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 134,441 shares of company stock valued at $2,025,041. Corporate insiders own 1.63% of the company’s stock.

Analyst Upgrades and Downgrades

TDOC has been the subject of several recent analyst reports. Royal Bank of Canada lowered their price target on Teladoc Health from $30.00 to $25.00 and set an “outperform” rating for the company in a report on Wednesday, February 21st. SVB Leerink assumed coverage on Teladoc Health in a report on Monday, February 26th. They issued a “market perform” rating and a $17.00 price target for the company. Canaccord Genuity Group decreased their target price on Teladoc Health from $34.00 to $28.00 and set a “buy” rating for the company in a report on Wednesday, February 21st. Citigroup decreased their target price on Teladoc Health from $21.00 to $19.00 and set a “neutral” rating for the company in a report on Wednesday, February 21st. Finally, Cantor Fitzgerald assumed coverage on Teladoc Health in a report on Thursday, February 29th. They set an “overweight” rating and a $22.00 target price for the company. Eight research analysts have rated the stock with a hold rating and six have assigned a buy rating to the company’s stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and an average target price of $22.43.

Teladoc Health Stock Performance

Shares of TDOC opened at $15.10 on Friday. The business’s 50 day moving average is $17.51 and its two-hundred day moving average is $18.58. Teladoc Health, Inc. has a 52-week low of $14.29 and a 52-week high of $30.41. The firm has a market cap of $2.52 billion, a price-to-earnings ratio of -11.27 and a beta of 0.94. The company has a quick ratio of 3.47, a current ratio of 3.54 and a debt-to-equity ratio of 0.66.

Teladoc Health (NYSE:TDOC) last announced its earnings results on Tuesday, February 20th. The health services provider reported ($0.17) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.05. The company had revenue of $660.50 million for the quarter, compared to analyst estimates of $670.79 million. Teladoc Health had a negative return on equity of 9.22% and a negative net margin of 8.47%. Teladoc Health’s quarterly revenue was up 3.6% on a year-over-year basis. During the same period in the prior year, the company posted ($0.23) EPS. Analysts forecast that Teladoc Health, Inc. will post -1.07 EPS for the current fiscal year.

Teladoc Health Company Profile

Teladoc Health, Inc provides virtual healthcare services worldwide. The company operates through Teladoc Health Integrated Care and BetterHelp segments. The Integrated Care segment offers virtual medical services, including general medical, expert medical, specialty medical, chronic condition management, and mental health, as well as enabling technologies and enterprise telehealth solutions for hospitals and health systems.